Systems Biology: A Therapeutic Target for Tumor Therapy
Open Access
- 23 July 2008
- journal article
- Published by Springer Science and Business Media LLC in Cancer Microenvironment
- Vol. 1 (1), 159-170
- https://doi.org/10.1007/s12307-008-0012-5
Abstract
Tumor-related activities that seem to be operationally induced by the division of function, such as inflammation, neoangiogenesis, Warburg effect, immune response, extracellular matrix remodeling, cell proliferation rate, apoptosis, coagulation effects, present itself from a systems perspective as an enhancement of complexity. We hypothesized, that tumor systems-directed therapies might have the capability to use aggregated action effects, as adjustable sizes to therapeutically modulate the tumor systems’ stability, homeostasis, and robustness. We performed a retrospective analysis of recently published data on 224 patients with advanced and heavily pre-treated (10% to 63%) vascular sarcoma, melanoma, renal clear cell, cholangiocellular, carcinoma, hormone-refractory prostate cancer, and multivisceral Langerhans’ cell histiocytosis enrolled in nine multi-center phase II trials (11 centers). Each patient received a multi-targeted systems-directed therapy that consisted of metronomic low-dose chemotherapy, a COX-2 inhibitor, combined with one or two transcription modulators, pioglitazone +/− dexamethasone or IFN-alpha. These treatment schedules may attenuate the metastatic potential, tumor-associated inflammation, may exert site-specific activities, and induce long-term disease stabilization followed by prolonged objective response (3% to 48%) despite poor monoactivity of the respective drugs. Progression-free survival data are comparable with those of reductionist-designed standard first-line therapies. The differential response patterns indicate the therapies’ systems biological activity. Understanding systems biology as adjustable size may break through the barrier of complex tumor-stroma-interactions in a therapeutically relevant way: Comparatively high efficacy at moderate toxicity. Structured systems-directed therapies in metastatic cancer may get a source for detecting the topology of tumor-associated complex aggregated action effects as adjustable sizes available for targeted biomodulatory therapies.Keywords
This publication has 51 references indexed in Scilit:
- PPARgamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulationMedical Hypotheses, 2008
- PPARα Deficiency in Inflammatory Cells Suppresses Tumor GrowthPLOS ONE, 2007
- Hypoxia signalling controls metabolic demandCurrent Opinion in Cell Biology, 2007
- Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progressionProceedings of the National Academy of Sciences of the United States of America, 2006
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's LymphomaClinical Cancer Research, 2006
- Suberoylanilide Hydroxamic Acid Enhances Gap Junctional Intercellular Communication via Acetylation of Histone Containing Connexin 43 Gene LocusCancer Research, 2005
- Progressive dysregulation of transcription factors NF-κB and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokinesAmerican Journal of Physiology-Cell Physiology, 2004
- Reversal of ras‐induced inhibition of gap‐junctional intercellular communication, transformation, and tumorigenesis by lovastatinMolecular Carcinogenesis, 1993
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986